Regulation (EC) No 726/2004

Regulation (EC) No 726/2004
Title	Regulation (EC) No 726/2004
Type	Regulation
Institution	European Parliament and Council of the European Union
Enacted	2004
Applicable	European Union
Subject	Medicinal products for human and veterinary use; authorisation and supervision

Regulation (EC) No 726/2004

Regulation (EC) No 726/2004 established an EU framework for the authorisation and supervision of medicinal products, creating a centralised procedure and strengthening pharmacovigilance, linking European Medicines Agency structures with European Commission decision-making and aligning with instruments like the European Parliament legislative acts and Council of the European Union measures. The regulation interacts with directives such as Directive 2001/83/EC and Directive 2001/82/EC, and it has influenced jurisprudence in the Court of Justice of the European Union and reviews by the European Court of Auditors.

Background and Legislative Context

The regulation was proposed in the aftermath of policy reviews involving the European Commission, legislative negotiation with the European Parliament, and trilogues influenced by member states represented in the Council of the European Union, following previous frameworks including Directive 2001/83/EC and responses to public health events like the Bovine spongiform encephalopathy crisis and the Contaminated blood scandal. Drafting referenced work by agencies such as the Committee for Medicinal Products for Human Use and consultative input from the World Health Organization and national competent authorities including Agence nationale de sécurité du médicament et des produits de santé and the Medicines and Healthcare products Regulatory Agency. The legislative text was adopted under co-decision procedures involving rapporteurs from the European Parliament Committee on the Environment, Public Health and Food Safety and the Council Working Party on Pharmaceuticals.

Scope and Key Provisions

The regulation defines centralised authorisation for products including biotechnology-derived medicines, orphan medicinal products, and advanced therapy medicinal products, intersecting with regimes such as the Orphan Drug Regulation and the Advanced Therapy Medicinal Products Regulation. It sets out obligations for marketing authorisations, manufacture oversight involving entities like the European Commission Directorate-General for Health and Food Safety, and pharmacovigilance rules that complement national systems in member states such as France, Germany, and Italy. The text specifies criteria for referral procedures involving the Pharmacovigilance Risk Assessment Committee and coordination with international partners including the European Centre for Disease Prevention and Control.

Roles and Responsibilities of the European Medicines Agency

Under the regulation the European Medicines Agency assumes central roles including scientific evaluation performed by committees such as the Committee for Medicinal Products for Human Use, safety oversight via the Pharmacovigilance Risk Assessment Committee, and coordination with the European Commission on opinion issuance and with national competent authorities like the Bundesinstitut für Arzneimittel und Medizinprodukte and the Agenzia Italiana del Farmaco. The Agency’s remit interacts with institutional actors including the European Parliament through accountability mechanisms, and operational links to bodies like the European Food Safety Authority for cross-sectoral matters and to international regulators such as the Food and Drug Administration for cooperation.

Marketing Authorisation Procedures and Centralised Authorisation

The regulation creates a centralised procedure whereby the European Medicines Agency delivers opinions that the European Commission converts into single marketing authorisations valid across the European Union, distinct from decentralised or mutual recognition procedures involving national agencies like the Medicines and Healthcare products Regulatory Agency and the Swedish Medical Products Agency. It outlines timelines, fee structures connected to the European Commission Directorate-General for Health and Food Safety, grounds for refusal, and mechanisms for post-authorisation changes with appeal routes that have been adjudicated by the Court of Justice of the European Union and litigated in national courts such as the Administrative Court of Bavaria.

Pharmacovigilance and Safety Monitoring

Pharmacovigilance provisions assign responsibilities to marketing-authorisation holders, the European Medicines Agency, and national competent authorities including the Agence européenne des médicaments partners, and establish the EudraVigilance database and the European network coordinated with the Pharmacovigilance Risk Assessment Committee. The regime interfaces with international surveillance systems like those of the World Health Organization and reporting obligations that have been tested by safety reviews for products such as vaccines for H1N1 influenza and medicines implicated in high-profile safety signals adjudicated in cases before the European Court of Human Rights-adjacent litigation and national tribunals.

Implementation, Amendments and Case Law

Implementation required transposition of related directives and operationalisation by the European Medicines Agency and national agencies including the Läkemedelsverket (Sweden) and the Finnish Medicines Agency. Subsequent amendments and delegated acts by the European Commission and regulatory updates influenced by the Pharmacovigilance Risk Assessment Committee have modified procedural details, while case law from the Court of Justice of the European Union—in cases involving parties such as pharmaceutical firms like GlaxoSmithKline and Roche—has clarified limits on delegated powers, confidentiality, and judicial review.

Impact and Criticism

The regulation has been credited with harmonising market access and improving risk management across the European Union, influencing industry players including Novartis and Sanofi and affecting innovation pathways for sectors highlighted by the European Biotechnology Industry Association, but it has faced criticism from stakeholders such as patient organisations, academic commentators at institutions like University College London, and national ministries of health for perceived bureaucratic complexity, resource burdens on small and medium-sized enterprises, and debates over transparency exemplified in disputes involving pharmaceutical companies and freedom of information requests before courts like the General Court of the European Union.

Category:European Union regulations